Can Rheumatoid Arthritis Treatments Reduce The Chance Of Heart Attack?

ent study has shown that the use of a combination ofDMARDS; and 4,943 took TNF-inhibitors. Exposure of
a tumor necrosis factor (TNF) inhibitor along withone group of patients to TNF-inhibitors (taken alone or
methotrexate therapy in people with rheumatoidin combination with methotrexate) was compared to
arthritis (RA) was associated with a reduction in heartthat of the other group taking methotrexate alone.
attack risk of 80 percent compared with patients usingDuring the study period, 441 patients suffered heart
methotrexate alone, according to research presentedattacks, of which eight percent were fatal.
recently at the American College of RheumatologyResearchers found that patients on a combination of
Annual Scientific Meeting in Boston, Mass.TNF-inhibitors with methotrexate treatment had a
Rheumatoid arthritis is a chronic, systemic, autoimmuneheart attack risk of only 20 percent of the risk
disease that not only causes pain, stiffness, swelling,compared to patients taking methotrexate alone.
and limitation of function in joints, but also damagesHowever, there was no statistical difference seen
internal organs as well.among patients who were taking TNF-inhibitors alone,
Approximately, 2.1 million Americans are afflicted withTNF-inhibitors with other DMARDs, other DMARD
RA, most of them women. As mentioned above, whiletherapies without methotrexate, or a combination of
joints are the principal areas affected by RA,DMARDs and methotrexate. Therefore, this reduction
inflammation can develop in other organs as well. Heartin cardiovascular events appears to be a function of
attacks, resulting from inflammation of the coronarythe combination of methotrexate and TNF-inhibitors.
vessels, are more common in RA sufferers.“TNF-inhibitor therapy, in combination with
Researchers recently studied the risk of heart attackmethotrexate, dramatically reduces the risk of heart
in patients using a TNF-inhibitor (a drug that blocksattacks in patients with RA and should be seriously
cytokines and can turn off the chronic inflammationconsidered— especially in high-risk
that causes destruction in RA), methotrexate (a drugpatients,” said Gurkirpal Singh, MD, clinical
used to treat RA by blocking the metabolism of cells)professor of medicine in the division of
and other disease modifying anti-rheumatic drugsgastroenterology at Stanford University School of
(DMARDs), which are a category of drugs used in RAMedicine, and an investigator in the study.
to slow down the disease progression, in a largeThe notion that RA is a potentially crippling disorder is
population of patients with RA—many of whomwidely accepted. However, what is not generally
were also taking aspirin.known is that it is a potentially lethal disease leading to
Using information obtained from MediCal,an increased risk of heart attack and stroke.
California’s Medicaid program, researchersIt is imperative that patients with RA understand the
studied patients over the age of 18, suffering from RA,systemic nature of this condition and the need for
who were treated with TNF-inhibitors, methotrexate, oraggressive intervention. This study lends more
other DMARDs, over a six-and-a-half year period.ammunition to the argument that patients with RA
A total of 19,233 patients with RA were identified. Theneed to be treated with a combination of
patients’ mean age was 55 years.methotrexate and biologic therapy to not only reduce
Approximately 79 percent were women. Of thesethe chances for crippling deformity but also to reduce
patients, 13,383 took methotrexate; 14,958 took otherthe likelihood of cardiovascular death.